Holen Sie sich die Stockscreener-App
4.3603
1.47%
-0.0697
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Evolus, Inc.(NasdaqGM: EOLS) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 13,669 Shares - MarketBeat
Evolus (NASDAQ:EOLS) Insider Rui Avelar Sells 3,119 Shares - MarketBeat
Avelar Rui sells Evolus (EOLS) shares worth $14815 By Investing.com - Investing.com Canada
Evolus CEO Moatazedi sells $64929 in shares - Investing.com
Avelar Rui sells Evolus (EOLS) shares worth $14815 - Investing.com
Evolus (EOLS) officer tax-driven sale of 3,119 shares under 10b5-1 plan - Stock Titan
Evolus (NASDAQ: EOLS) insider sells 13,669 shares to cover taxes - Stock Titan
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus CEO Moatazedi sells $570k in shares By Investing.com - Investing.com India
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock - MarketBeat
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock By Investing.com - Investing.com Australia
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com Australia
Evolus CEO Moatazedi sells $570k in shares - Investing.com
Evolus (EOLS) executive sells 29,996 shares after PSU vesting - Stock Titan
(EOLS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Dip Buying: What is the earnings history of Evolus IncMarket Sentiment Review & Safe Entry Point Identification - baoquankhu1.vn
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Jobs Data: Whats the beta of Evolus Inc stockTrade Entry Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Divisadero Street Capital Management LP Makes New $2.38 Million Investment in Evolus, Inc. $EOLS - MarketBeat
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference - Yahoo Finance
Evolus (NASDAQ:EOLS) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026) - Minichart
Evolus reclassifies Vikram Malik to Class II director to balance board - Investing.com
Evolus reclassifies Vikram Malik to Class II director to balance board By Investing.com - Investing.com UK
Vikram Malik reclassified to Class II director at Evolus - TradingView
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance - Stock Titan
Evolus, Inc. Announces Executive Changes, Effective March 13, 2026 - marketscreener.com
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance
Evolus at Leerink Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
New Highs: What is the earnings history of Evolus IncMarket Growth Review & High Win Rate Trade Tips - baoquankhu1.vn
Evolus Earnings Call Signals Growth Amid Headwinds - The Globe and Mail
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Market Outlook: What analysts say about Evolus Inc stockTrade Ideas & Short-Term High Return Strategies - baoquankhu1.vn
Bank Watch: Can Evolus Inc navigate macro headwindsPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
(EOLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Can Evolus Inc. stock maintain growth trajectoryChart Signals & Community Consensus Trade Alerts - Naître et grandir
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - MarketBeat
Why Evolus Stock Soared Today - AOL.com
Evolus, Inc. (EOLS) matches Q4 earnings estimates - MSN
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Evolus (EOLS), Aldeyra Therapeutics (ALDX) - The Globe and Mail
Data Privacy Compliance Risks Threaten Evolus’s Operations and Financial Health - TipRanks
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
Evolus (EOLS) Nears Breakeven In Q4 EPS Challenging Prolonged Loss Narratives - simplywall.st
Evolus Q4 2025 slides: revenue growth continues despite forecast miss - Investing.com Australia
EOLS SEC FilingsEvolus 10-K, 10-Q, 8-K Forms - Stock Titan
Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha
Midday Stock Roundup: Evolus, Xponential up - Orange County Business Journal
Evolus Up Over 26%, on Pace for Largest Percent Increase Since January 2025 -- Data Talk - 富途牛牛
Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results - MarketBeat
Evolus' (EOLS) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Evolus, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
US Stock Movement | Evolus rises over 16% pre-market as Q4 revenue growth achieves breakeven, positive guidance for this quarter - Bitget
Evolus (EOLS) Projects Growth with Strategic Initiatives and New Product Launches - GuruFocus
3.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):